SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

Share Price is delayed by 15 minutes
Get Live Data
17.00    0.00 (0.00%)
Bid:
16.00
Ask:
18.00
Spread: 2.00 (12.50%)
Market Cap: £12.86m
FIPP Live PriceLast checked at - London Stock Exchange

Intraday Frontier Ip Share Chart

Cambridge Material Testing Solutions

19 Jun 2018 07:00

RNS Number : 7039R
Frontier IP Group plc
19 June 2018
 

RNS REACH / RNS

AIM: FIPP

19th June 2018

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

 

Portfolio news - New Portfolio Company, Cambridge Material Testing Solutions

 

 

Frontier IP, which specialises in commercialising university intellectual property, today announces it has taken a 24 per cent stake in Cambridge Material Testing Solutions ("the Company"), a business established to support the work of Dr James Dean, an expert in the mechanics and deformation of materials.

 

The Company is developing software and hardware to measure material characteristics in critical metal components more swiftly, cost effectively, and accurately than other systems. Among other potential benefits is mobile and remote testing on site, and the ability to assess complex components and joints.

 

The technology has a very wide range of applications in several sectors, including in the aerospace, nuclear, and oil and gas industries where material degradation and component life assessment of high value assets is critically important.

 

Currently, the hardware used to measure material characteristics forces a hard tip into a metal surface to create an indent. The material response characteristics are measured, allowing simple measurements of hardness and stiffness to be made. Existing indentation test equipment is bulky and laboratory based.

 

Cambridge Material Testing Solutions is addressing the materials testing challenges facing industry by focusing on two development areas:

 

o a suite of software tools, called SEMPID. This can process data generated by existing indentation test equipment and swiftly convert it into information easily understood by engineers to assess the strength and remaining working life of metal components;

 

o customised indentation test equipment. The new systems will be desktop-based, mobile, or fixed on site to assess critical components while in service.

 

Dr James Dean received his PhD from the Department of Materials Science at the University of Cambridge. He has worked for Frazer Nash Consultancy, a leading systems and engineering technology company, on a number of projects, mainly in the nuclear and aerospace industries. He then joined Double Precision Consultancy, a specialist in tackling complex engineering challenges.

 

 

More details about the technology are below.

 

Frontier IP Chief Executive Officer Neil Crabb said: "Frontier IP is delighted to be working with Dr. James Dean and his team to help accelerate the commercialisation of this exciting technology. We believe Cambridge Material Testing Solutions could prove invaluable to companies in critical sectors which need to ensure the materials they use are safe and robust."

 

Cambridge Material Testing Solutions' Chief Technology Officer, Dr. James Dean said: "Our partnership with Frontier IP is further confirmation of our proposition's value. With Frontier IP's expertise in the commercialisation of advanced technologies and its ready access to the sectors we intend to penetrate, where the accurate and non-destructive characterisation of material properties is crucial to the safe operation of high value assets."

 

ENQUIRIES

 

Frontier IP Group Plc

T: 0131 240 1251

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

 

M: 07464 546 025

Cenkos Securities plc (Nominated Adviser and Joint Broker)

T: 0131 220 6939

Neil McDonald / Beth McKiernan

Peterhouse Corporate Finance Limited (Joint Broker)

T: 020 7469 0935

Lucy Williams

Kreab (Financial PR)

T: 020 7074 1800

Robert Speed / Matthew Jervois

 

About the Cambridge Materials Testing Solutions technology:

The Company is initially developing a suite of user-friendly software packages that allow rapid and accurate evaluation of the parameters that characterise mechanical properties (such as yield stress and work hardening rate) from instrumented indentation tests. These non-destructive tests are quick and easy to carry out.

 

Another major attraction is that such experiments require only small samples of simple shape (such as plates of mm dimensions), while mapping of local properties over the surface of larger samples is also possible.

 

The suite of software packages, called SEMPID (Software for the Extraction of Material Properties from Indentation Data), are application specific tools for converting indentation data into mechanical material parameters and stress-strain curves.

 

An application for the calculation of stress-strain curves (plasticity parameters) is already available in beta version. This application can process data generated during an indentation test (load-displacement curves or residual indent shapes) and swiftly convert it into stress-strain data that can subsequently be used to assess the strength and remaining working life of metal components.

 

Their software solutions can significantly reduce materials testing turnaround times and materials testing costs.

 

In addition, and as part of their proposed portfolio of materials testing solutions, the Company is developing a customised suite of indentation test equipment including a bespoke desktop-based indenter, and a portable indenter for remote testing of in-service and on-site components.

 

NOTES TO EDITORS

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income from by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRASFESUAFASELM
Date   Source Headline
26th May 20267:00 amRNS-RPortfolio news: Dekiln strategic partnership
5th May 20267:00 amRNSAppointment of Chief Financial Officer
16th Apr 20264:07 pmRNSHolding(s) in Company
15th Apr 20267:00 amRNSPortfolio News: 2D Photonics subsidiary grant
13th Apr 20262:35 pmRNSHolding(s) in Company
10th Apr 202610:30 amRNSUpdate re Investee Company
8th Apr 20267:00 amRNS-RPortfolio news – Fieldwork Robotics £3M fundraise
31st Mar 20265:18 pmRNSHolding(s) in Company
30th Mar 20267:00 amRNSUnaudited Half Year Results
23rd Mar 20267:00 amRNS-RAlusid reaches milestone in European roll out
28th Jan 20264:28 pmRNSHolding(s) in Company
19th Jan 20267:00 amRNS-RPortfolio news - Strong results for TVG vaccine
12th Jan 202610:30 amRNSHolding(s) in Company
31st Dec 20251:00 pmRNSTotal Voting Rights
31st Dec 20251:00 pmRNSTotal Voting Rights
31st Dec 202512:30 pmRNSResult of AGM
31st Dec 202512:30 pmRNSResult of AGM
29th Dec 20252:37 pmRNSHolding(s) in Company
29th Dec 20252:37 pmRNSHolding(s) in Company
24th Dec 20259:52 amRNSHolding(s) in Company
24th Dec 20259:52 amRNSHolding(s) in Company
24th Dec 20257:00 amRNSHolding(s) in Company
23rd Dec 20252:17 pmRNSDirectors' Shareholdings
23rd Dec 20252:17 pmRNSDirectors’ Shareholdings
22nd Dec 20253:48 pmRNSResult of Retail Offer
22nd Dec 20253:48 pmRNSResult of Retail Offer
18th Dec 20259:15 amRNS-RDekiln benefits from £3 million funding
17th Dec 202511:54 amRNSResult of Placing and Subscription
17th Dec 20257:01 amRNSRetail Offer
17th Dec 20257:00 amRNSProposed Placing and Subscription to raise £870k
15th Dec 20257:00 amRNS-RPortfolio news- Alusid £500k pre-IPO funding round
10th Dec 20254:56 pmRNSHolding(s) in Company
9th Dec 20257:00 amRNSPosting of Annual Report & Notice of AGM
8th Dec 20257:00 amRNSFinal results for the year ended 30 June 2025
2nd Dec 20257:00 amRNS-RAlusid signs Swedish distribution agreement
6th Nov 20257:00 amRNSBord Change
3rd Nov 20257:00 amRNS-RTVG demonstrates success in animal trials
20th Oct 20257:00 amRNS-RAmprologix raises £740,000 in Pre-Series A round
25th Sep 20257:00 amRNSBoard Changes
24th Sep 20255:12 pmRNSHolding(s) in Company
13th Jun 20257:00 amRNSStrategic partnership for Cambridge innovation hub
10th Jun 20257:00 amRNS-RAlusid signs international distribution agreement
6th May 20257:00 amRNS-RTVG's vaccine candidate enters animal trials
16th Apr 20257:00 amRNS-RSyva signs option to license agreement with TVG
2nd Apr 20254:47 pmRNSDirector/PDMR Shareholding
31st Mar 20251:02 pmRNSDirector/PDMR Shareholding
26th Mar 20257:00 amRNSUnaudited Half Year Results
24th Mar 20257:00 amRNSCamGraphIC secures €25 million in Series A funding
18th Mar 20257:00 amRNS-RPulsiv wins PSMA’s Global Energy Efficiency Award
25th Feb 20257:00 amRNS-RGraphEnergyTech collaboration & Innovate UK grant

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.